ランキングに戻る

Novanta Inc. (NOVT)

割高
TechnologyScientific & Technical InstrumentsUnited States

ファンダメンタル

55

株価

$143.99

時価総額

$5.38B

パート1 · 企業の価値

概要

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users

P/E: 69.9Score: 63Market cap: $55.31B

Named by Novanta as a major Photonics competitor: it supplies the same OEM customers with laser sources, optics and beam-delivery subsystems for industrial processing and medical devices.

SCANLAB GmbHNot tracked

Named by Novanta as a major Photonics competitor: both sell galvanometer-based laser beam-steering scan heads to the same industrial and medical laser-system builders.

OMRON Corporation (オムロン株式会社)6645

Novanta names Omron Microscan Systems as a major Vision competitor: the two compete for the same factory-automation and medical-device OEMs buying machine vision and barcode reading subsystems.

Renishaw plcRSW

Named by Novanta as a major Precision Motion competitor: both sell optical encoders and precision position-feedback devices to machine-tool, semiconductor and medical equipment makers.

Barco NVBAR

Named by Novanta as a major Vision competitor: Barco's healthcare visualization business competes directly with Novanta's surgical and diagnostic display systems sold to medical OEMs and hospitals.

Physik Instrumente (PI) SE & Co. KGNot tracked

Named by Novanta as a major Precision Motion competitor: both supply precision positioning stages and motion subsystems to the same photonics, semiconductor and life-science instrument builders.

貸借対照表と流動性

売上高

$1.03B

直近12か月(2026/7/3まで)

純利益

$62M

直近12か月(2026/7/3まで)

フリーキャッシュフロー

$48M

自己資本合計

$1.31B

負債合計

$493M

流動比率

4.57

利払い倍率

-

負債/EBITDA

1.83

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース割高

適正価値

$89.83

現在株価

$143.99

安全マージン

-60.3%

適正価値レンジ

$58.39 - $121.27

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:$194.50
ディスカウンテッド・キャッシュフロー(DCF):$34.60
利益倍率(P/E):$54.22
グレアムの成長公式:$20.89
収益力価値(EPV):$12.62
正当化されたP/B:$7.67
配当割引モデル(ゴードン):算出に必要なデータが不足しています
P/FFO(運用から生まれる資金):$48.98
中間サイクル利益:$63.07
売上高倍率:$127.68
アナリスト・コンセンサス:強い買い (8B / 1H / 0S)
直近の決算サプライズ:+5.13%

バリュエーション指標

P/E レシオ

90.57

ROE

4.1%

P/B レシオ

3.33

P/FCF

47.05

粗利益率

44.5%

ROIC

3.9%

収益性レーダー

価値創造(経済的モート)

ROIC

3.9%

WACC

13.3%

ROIC − WACC

-9.5 pp

ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。

ファンダメンタル分析基準

合格(16)

  • EPS shows upward trend
  • Price CAGR 21.27%
  • Gross Margin 44.5%
  • Debt/Equity ratio
  • Operating Margin 9.0%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Revenue Growth 5Y 10.7%
  • Analyst Consensus 89% Buy
  • Earnings Surprise avg 3.3%
  • Earnings Quality (OCF/NI) 2.17
  • Share Dilution 1.1%
  • Piotroski F-Score 5/9

不合格(9)

  • ROIC 3.8%
  • P/FCF 47.05
  • P/B Ratio 3.33
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 4.9%
  • PEG Ratio 26.26
  • Net Margin Trend 6.0% vs 6.4%

データなし(2)

  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-スコア

5/9

まちまちのシグナル:一部の領域に注意が必要

score
criteria

利益の質

2.17

高品質:利益はキャッシュに裏付けられている

株式希薄化

1.1%

株式数は安定している

機関投資家の保有

ガバナンス

経営陣

氏名役職年齢
Mr. Matthijs GlastraCEO & Chairman of the Board56
Mr. Robert J. BuckleyChief Financial Officer51
Mr. Alexander ManganielloGeneral Counsel & Corporate Secretary58
Mr. Charles G. RavettoCo-Chief Operating Officer of Automation Enabling Technologies54
Mr. John LesicaCo-Chief Operating Officer of Medical Solutions49
Mr. John Joseph Burke IIChief Accounting Officer & Corporate Controller43
Ms. Sarah BetadamChief Information Officer & Chief Information Security Officer-
Ms. Nissia SabriSenior Vice President of Corporate Development-
Mr. Liam WestonChief Human Resources Officer-
Mr. Heinrich DreyerGroup President of Medical Solutions-

監査リスク

2

取締役会リスク

4

報酬リスク

4

株主権利リスク

2

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

書類

  • 年次報告書(10-K)

    事業内容、財務実績、リスクをまとめた年次の概要。

    提出日: 2026-02-23

    書類を見る
  • 四半期報告書(10-Q)

    直近3か月間の業績に関する最新情報。

    提出日: 2026-08-05

    書類を見る
  • 臨時報告書(8-K)

    経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

    提出日: 2026-08-05

    書類を見る

via SEC EDGAR

業績推移

via SEC EDGAR

Latest News

Recent headlines for NOVT, sourced from Markets Gazette.

  • 3/4/2026POSITIVE
    Novanta Stock Has Underperformed This Past Year, but One Investor Just Made a $36 Million Bet on Shares

    Despite underperforming over the past year, Novanta Inc. (NOVT) has attracted a significant bet from an investor who purchased $36 million worth of shares. This bold move suggests strong conviction in the company's future recovery and growth potential. Novanta designs photonics and precision motion solutions for OEMs in medical and industrial markets globally. While the stock has lagged, this substantial investment could signal a turning point, indicating that the company's underlying value is underestimated by the market and may lead to a positive re-evaluation.

  • 2/24/2026NEUTRAL
    Novanta (NOVT) Q4 2025 Earnings Call Transcript

    Markets Gazette notes the release of the earnings call transcript for Novanta Inc. (NOVT) concerning its fourth-quarter 2025 results. While specific financial figures and future projections have not yet been made public or analyzed herein, the availability of this document is a key event for investors. Earnings call transcripts provide direct insights into company performance, management strategies, challenges faced, and growth prospects, often revealing the tone and expectations of leadership. Shareholders and analysts will closely monitor this document for any implicit or explicit signals that could influence the stock's value in the short to medium term. The current lack of specific content necessitates a cautious approach, but the transcript remains a crucial resource for due diligence.

  • 2/23/2026NEUTRAL
    A Preview Of Novanta's Earnings

    The Markets Gazette notes that investor focus is turning to Novanta Inc. ahead of its upcoming earnings release. The article, while providing no specific data, serves as a calendar marker for a key event that could define the stock's short-term trajectory. Analysts and the market are awaiting crucial figures such as revenue, earnings per share (EPS), and, most importantly, forward-looking guidance for the coming quarters. The stock's reaction will largely depend on how the actual results compare against consensus estimates. Until the official announcement, traders are likely to maintain a cautious stance, with trading volumes potentially increasing closer to the release date, signaling heightened anticipation.

  • 2/22/2026NEGATIVE
    Is Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?

    Novanta Inc., a leader in photonics and precision motion solutions for OEMs, has experienced notable insider selling. The CEO recently offloaded 6,500 shares, a move that could signal diminished confidence in the company's future performance from top management. While Novanta operates in promising tech sectors, this insider action might concern investors, suggesting the current stock price could be considered high or that potential challenges lie ahead not yet fully reflected in the market. Investors should closely watch upcoming financial reports and operational performance to assess the impact of this sale.

via Markets Gazette